Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:CEMI's Cash-to-Debt is ranked higher than
95% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.94 vs. NAS:CEMI: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:CEMI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.21  Med: 97.5 Max: No Debt
Current: No Debt
Equity-to-Asset 0.84
NAS:CEMI's Equity-to-Asset is ranked higher than
86% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. NAS:CEMI: 0.84 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:CEMI' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.07  Med: 0.65 Max: 0.85
Current: 0.84
-2.07
0.85
Piotroski F-Score: 4
Altman Z-Score: 9.24
Beneish M-Score: -3.90
WACC vs ROIC
13.81%
-136.90%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -42.38
NAS:CEMI's Operating Margin % is ranked lower than
68% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.35 vs. NAS:CEMI: -42.38 )
Ranked among companies with meaningful Operating Margin % only.
NAS:CEMI' s Operating Margin % Range Over the Past 10 Years
Min: -42.38  Med: -1.66 Max: 15.41
Current: -42.38
-42.38
15.41
Net Margin % -74.70
NAS:CEMI's Net Margin % is ranked lower than
73% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. NAS:CEMI: -74.70 )
Ranked among companies with meaningful Net Margin % only.
NAS:CEMI' s Net Margin % Range Over the Past 10 Years
Min: -74.7  Med: -1.16 Max: 32.02
Current: -74.7
-74.7
32.02
ROE % -82.34
NAS:CEMI's ROE % is ranked lower than
79% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.09 vs. NAS:CEMI: -82.34 )
Ranked among companies with meaningful ROE % only.
NAS:CEMI' s ROE % Range Over the Past 10 Years
Min: -497.86  Med: -1.29 Max: 67.84
Current: -82.34
-497.86
67.84
ROA % -68.84
NAS:CEMI's ROA % is ranked lower than
78% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.86 vs. NAS:CEMI: -68.84 )
Ranked among companies with meaningful ROA % only.
NAS:CEMI' s ROA % Range Over the Past 10 Years
Min: -68.84  Med: -1.03 Max: 50.54
Current: -68.84
-68.84
50.54
ROC (Joel Greenblatt) % -105.39
NAS:CEMI's ROC (Joel Greenblatt) % is ranked lower than
62% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. NAS:CEMI: -105.39 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:CEMI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -192.05  Med: -1.05 Max: 98.41
Current: -105.39
-192.05
98.41
3-Year Revenue Growth Rate -18.50
NAS:CEMI's 3-Year Revenue Growth Rate is ranked lower than
80% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. NAS:CEMI: -18.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:CEMI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -1.05 Max: 59.4
Current: -18.5
0
59.4
GuruFocus has detected 3 Warning Signs with Chembio Diagnostics Inc $NAS:CEMI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:CEMI's 10-Y Financials

Financials (Next Earnings Date: 2017-06-08 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

CEMI Guru Trades in Q4 2015

Jim Simons 13,100 sh (New)
» More
Q1 2016

CEMI Guru Trades in Q1 2016

Jim Simons 13,900 sh (+6.11%)
» More
Q2 2016

CEMI Guru Trades in Q2 2016

Jim Simons 48,200 sh (+246.76%)
» More
Q3 2016

CEMI Guru Trades in Q3 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CEMI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325413    SIC: 2835
Compare:OTCPK:EDTXF, NAS:CGIX, NAS:HTGM, AMEX:PTN, OTCPK:PRFMF, NAS:BIOC, OTCPK:SYGWF, NAS:CDNA, NAS:CHEK, NAS:CAPN, NAS:DRIO, OTCBB:INIS, NAS:PMD, NAS:TROV, AMEX:VNRX, OTCPK:TDSGF, OTCPK:GNWSF, OTCPK:ILIU, NAS:WGBS, NAS:AIQ » details
Chembio Diagnostics Inc develops, manufacture market & licenses rapid point of care diagnostic tests that detect infectious diseases. Its products are rapid tests for the detection of HIV 1/2 antibodies, & for the detection of HIV & Syphilis antibodies.

Chembio Diagnostics Inc was formed in 1985. The Company with its subsidiaries develops, manufactures and markets diagnostic tests that detect infectious diseases. The Company's main products presently commercially available are four rapid tests for the detection of HIV antibodies in whole blood, serum and plasma samples, all of which Employ lateral flow technology, and two of which were approved by the FDA in 2006. The Company's products are sold to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals and retail establishments both domestically and internationally. The Company's products are sold under its STAT PAK, SURE CHECK or DPP registered trademarks. The Company's HIV tests are qualitative (reactive/non-reactive) tests. Many of its competitors are substantially larger and have greater financial, research, manufacturing and marketing resources. The manufacturing and marketing of the Company's existing and proposed diagnostic products are regulated by the United States Food and Drug Administration ('FDA'), United States Department of Agriculture ('USDA'), certain state and local agencies, and/or comparable regulatory bodies in other countries.

Ratios

vs
industry
vs
history
PB Ratio 3.72
CEMI's PB Ratio is ranked lower than
55% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.38 vs. CEMI: 3.72 )
Ranked among companies with meaningful PB Ratio only.
CEMI' s PB Ratio Range Over the Past 10 Years
Min: 1.39  Med: 3.13 Max: 20.71
Current: 3.72
1.39
20.71
PS Ratio 3.01
CEMI's PS Ratio is ranked higher than
52% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.29 vs. CEMI: 3.01 )
Ranked among companies with meaningful PS Ratio only.
CEMI' s PS Ratio Range Over the Past 10 Years
Min: 0.17  Med: 1.39 Max: 4.07
Current: 3.01
0.17
4.07
EV-to-EBIT -7.24
CEMI's EV-to-EBIT is ranked lower than
99.99% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.11 vs. CEMI: -7.24 )
Ranked among companies with meaningful EV-to-EBIT only.
CEMI' s EV-to-EBIT Range Over the Past 10 Years
Min: -53.1  Med: -2.2 Max: 156.9
Current: -7.24
-53.1
156.9
EV-to-EBITDA -8.52
CEMI's EV-to-EBITDA is ranked lower than
99.99% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 15.75 vs. CEMI: -8.52 )
Ranked among companies with meaningful EV-to-EBITDA only.
CEMI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -328.9  Med: -2.4 Max: 42.9
Current: -8.52
-328.9
42.9
Current Ratio 5.32
CEMI's Current Ratio is ranked higher than
81% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. CEMI: 5.32 )
Ranked among companies with meaningful Current Ratio only.
CEMI' s Current Ratio Range Over the Past 10 Years
Min: 0.73  Med: 3.21 Max: 5.32
Current: 5.32
0.73
5.32
Quick Ratio 4.34
CEMI's Quick Ratio is ranked higher than
78% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.08 vs. CEMI: 4.34 )
Ranked among companies with meaningful Quick Ratio only.
CEMI' s Quick Ratio Range Over the Past 10 Years
Min: 0.4  Med: 2.43 Max: 5
Current: 4.34
0.4
5
Days Inventory 133.37
CEMI's Days Inventory is ranked lower than
72% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.07 vs. CEMI: 133.37 )
Ranked among companies with meaningful Days Inventory only.
CEMI' s Days Inventory Range Over the Past 10 Years
Min: 58.96  Med: 75.64 Max: 133.96
Current: 133.37
58.96
133.96
Days Sales Outstanding 69.13
CEMI's Days Sales Outstanding is ranked lower than
60% of the 148 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.89 vs. CEMI: 69.13 )
Ranked among companies with meaningful Days Sales Outstanding only.
CEMI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 26.72  Med: 56.58 Max: 110.1
Current: 69.13
26.72
110.1
Days Payable 45.74
CEMI's Days Payable is ranked lower than
60% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.49 vs. CEMI: 45.74 )
Ranked among companies with meaningful Days Payable only.
CEMI' s Days Payable Range Over the Past 10 Years
Min: 32.15  Med: 39.97 Max: 49.36
Current: 45.74
32.15
49.36

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.90
CEMI's 3-Year Average Share Buyback Ratio is ranked lower than
59% of the 133 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. CEMI: -8.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CEMI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -244.7  Med: -54.9 Max: 46.7
Current: -8.9
-244.7
46.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 8.98
CEMI's Price-to-Net-Cash is ranked higher than
58% of the 84 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.27 vs. CEMI: 8.98 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CEMI' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 5.91  Med: 17.35 Max: 30.86
Current: 8.98
5.91
30.86
Price-to-Net-Current-Asset-Value 4.34
CEMI's Price-to-Net-Current-Asset-Value is ranked higher than
76% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.90 vs. CEMI: 4.34 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CEMI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.2  Med: 5.51 Max: 37.33
Current: 4.34
2.2
37.33
Price-to-Tangible-Book 3.71
CEMI's Price-to-Tangible-Book is ranked higher than
64% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.19 vs. CEMI: 3.71 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CEMI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.58  Med: 4.01 Max: 17.78
Current: 3.71
1.58
17.78
Price-to-Intrinsic-Value-Projected-FCF 265.00
CEMI's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
100% of the 88 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.31 vs. CEMI: 265.00 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CEMI' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.53  Med: 4.12 Max: 340
Current: 265
1.53
340
Price-to-Median-PS-Value 2.17
CEMI's Price-to-Median-PS-Value is ranked lower than
90% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. CEMI: 2.17 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CEMI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.27  Med: 1.05 Max: 2.78
Current: 2.17
0.27
2.78
Earnings Yield (Greenblatt) % -13.81
CEMI's Earnings Yield (Greenblatt) % is ranked lower than
72% of the 269 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.54 vs. CEMI: -13.81 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CEMI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -13.81  Med: 4.4 Max: 12128.3
Current: -13.81
-13.81
12128.3

More Statistics

Revenue (TTM) (Mil) $17.87
EPS (TTM) $ -1.28
Beta1.52
Short Percentage of Float1.72%
52-Week Range $5.05 - 9.40
Shares Outstanding (Mil)12.30

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 22 30
EPS ($) -0.51 -0.07
EPS without NRI ($) -0.51 -0.07
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CEMI

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Chembio Diagnostics, Inc. :CEMI-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017 Mar 17 2017
Chembio Diagnostics, Inc. :CEMI-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017 Mar 15 2017
CHEMBIO DIAGNOSTICS, INC. Financials Mar 11 2017
CEMI: Surprise Rebound In Lateral Flow, Expect DPP Strong Showing In 2017 Mar 10 2017
Chembio Diagnostics Reports 2016 Financial Results Mar 07 2017
CHEMBIO DIAGNOSTICS, INC. Files SEC form 10-K, Annual Report Mar 07 2017
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Mar 07 2017
Q4 2016 Chembio Diagnostics Inc Earnings Release - After Market Close Mar 07 2017
Investor Network Invites You to the Chembio 2016 Year-End Earnings Conference Call and Webcast Live... Mar 06 2017
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Feb 28 2017
Chembio to Host Conference Call to Discuss 2016 Financial Results Feb 27 2017
Chembio Appoints Sales Executives in Latin America, Africa, Asia Pacific Jan 26 2017
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 17 2017
Chembio’s DPP® HIV-Syphilis Assay Receives CE Mark for Simultaneous Point-of-Care Detection of... Jan 17 2017
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Jan 10 2017
Chembio Completes Acquisition of Malaysia-based RVR Diagnostics Jan 10 2017
ETFs with exposure to Chembio Diagnostics, Inc. : January 9, 2017 Jan 09 2017
ETFs with exposure to Chembio Diagnostics, Inc. : December 30, 2016 Dec 30 2016
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Dec 13 2016
ETFs with exposure to Chembio Diagnostics, Inc. : November 14, 2016 Nov 14 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)